Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study for the Determination of Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome With Favorable Risk Profile

NCT00977132 is registered in ClinicalTrials.gov with Heinrich-Heine University, Duesseldorf as lead sponsor.

NCT NCT00977132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00977132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study for the Determination of Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome With Favorable Risk Profile
Lead sponsor
Heinrich-Heine University, Duesseldorf
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2009
Completion date
May 31, 2014
Enrollment
23 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome mds